



Dynavax to Webcast Presentation at Future Leaders in the Biotech Industry Conference, April 7, 2005

BERKELEY, Calif., March 29 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, MD, President and CEO, will present an overview of the company at the Thomson Financial/BioCentury Future Leaders in the Biotech Industry conference at the Millennium Broadway hotel in New York City.

Dr. Dina's presentation will be webcast live at 11:40 am ET on Thursday, April 7, 2005. The webcast presentation may be accessed by visiting http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=DVAX&item_id=1015249, where it will also be archived for 30 days following the presentation.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. ISS are being developed in three initial indications: ragweed allergy immunotherapeutic, currently in a Phase 2/3 clinical trial; a Hepatitis B vaccine, currently in a Phase 2/3 clinical trial; and an asthma immunotherapeutic that has completed a Phase 2 exploratory trial.

SOURCE Dynavax Technologies Corporation
03/29/2005

CONTACT: Jane M. Green, PhD, Vice President, Corporate Communications of Dynavax Technologies Corporation, +1-510-665-4630, or jgreen@dvax.com

Web site: <http://www.dynavax.com>
(DVAX)

03/29/2005 06:00 EST <http://www.prnewswire.com>